Quantcast

IMCOR Pharmaceutical Co. Ultrasound Contrast Agent Imagent Featured in Four Presentations at the RSNA in Chicago

November 29, 2004

IMCOR Pharmaceutical Co. (Nasdaq:ICPHC) announced today that Dr. Ethan Halpern of Thomas Jefferson University Hospital presented the results of two papers at the Radiological Society of North America Meeting on the use of Imagent(R) (perflexane lipid microsphere) in the detection of prostate cancer. Dr. Robert Mattrey of University of California San Diego Medical Center presented the results of a clinical study investigating the use of Imagent with chemoembolization for detection of tumor vascularity, and additionally the results on the use of Imagent in an animal model for the detection of tumor angiogenesis.

Dr. Halpern’s presentations, Prostate Cancer Detection with Targeted Biopsy during Contrast Enhanced Sonography and Detection of Prostate Cancer with Contrast Enhanced Sonography Using Harmonic Gray Scale, Color Doppler, and Power Doppler Imaging, were presented Sunday, November 28, 2004. Both presentations outlined the results of a 301 patient clinical study to evaluate cancer detection with contrast enhanced targeted biopsy. The results showed that the detection rate of cancer in contrast enhanced targeted biopsy cores is higher compared to standard sextant approach. The second paper results showed that there was statistical improvement in discrimination between benign and malignant areas within the prostate outer gland. Overall, more study is needed to improve visualization of the apex of the prostate and to improve the technique for differentiation of benign from malignant tissue based on visual criteria.

On Monday, November 29, 2004, Dr. Mattrey presented Early Assessment of Treatment Success with Contrast Enhanced Ultrasound Post Transarterial Chemoembolization for Hepatocellular Carcinoma and The Use of Contrast Enhanced High Resolution Ultrasound Imaging to Detect Early Changes in Tumor Vascularity. In the first study, 29 patients were investigated to determine residual blood flow in tumors following chemoembolization and it was found that the outcome with contrast enhanced ultrasound using Imagent was predictable in 1 week following treatment compared to 3 months following CT or MRI. In the second study, in which VX-2 tumors in rabbits were injected with the angiogenesis inhibitor, TNP-470, contrast enhanced ultrasound using Imagent allowed visualization of tumor blood flow in response to the anti-angiogenesis treatment.

Dr. Taffy Williams, President of IMCOR stated that, “We are pleased to support the ongoing pre-clinical and clinical development of Imagent in such prestigious research institutions. Although Imagent is currently approved for cardiac indications, and is soon to enter Phase II clinical trials for myocardial perfusion, IMCOR is interested in evaluating Imagent in non-cardiac indications.”

About IMCOR

IMCOR Pharmaceutical Co. is a specialty pharmaceutical company developing and marketing a platform of innovative imaging products. Its FDA approved product, Imagent, is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and thereby improve visualization of the main pumping chamber of the heart, and to improve delineation of the endocardial borders (walls) of the heart. As a result, ultrasound with Imagent may better distinguish normal and abnormal heart structure and function — two critical indicators of cardiac health. Imagent is also being investigated to measure myocardial perfusion to determine the location and extent of blockage of the major coronary arteries. Imagent is manufactured from synthetic materials, and packaged as a dry powder in a ready-to-use kit that is stored at room temperature.

IMCOR’s development programs include the use a versatile iodinated nanoparticulate formulation, PH-50, that shows promise as a CT cardiovascular imaging agent and lymphography imaging agent.

Statements in this release that are not strictly historical are “forward-looking” statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks that may cause IMCOR’s actual results in the future to differ materially from expected results. These risks and uncertainties include the ability of the company to: obtain necessary financing to support its development and commercialization programs, maintain and defend intellectual property protection for its proprietary products, avoid infringing intellectual property rights of third parties, successfully market its approved product, develop additional products and obtain regulatory approval for their use, and manufacture or obtain supplies of drug product. These and other risks are described and qualified in their entirety by cautionary language and risk factors set forth in the company’s filings from time to time with the Securities and Exchange Commission.




comments powered by Disqus